We are advancing a pipeline of novel biologics designed for pan-amyloid removal – across all stages and types of systemic amyloidosis. In support of our paradigm-changing therapeutics, we are also developing the world’s first amyloidosis-specific diagnostic imaging agent which has the potential to set a new standard in the diagnosis of systemic amyloid and identify the many patients that remain undiagnosed.
There are currently no treatments to remove amyloid in patients with systemic amyloidosis. Current treatments are applicable for some types of amyloidosis and reduce new amyloid formation which may slow disease progression. However, none of these existing therapies directly address the toxic amyloid already deposited in organs that leads to progressive organ failure and increased mortality.
We are focused on addressing this unmet need for an amyloidosis therapy capable of broadly removing existing amyloid deposits, opening the door to improving organ function and reversing disease for patients with all types of systemic amyloidosis.
Mark Timney has deep experience in the biopharmaceutical industry. He has repeatedly distinguished himself as a corporate leader who delivers value for patients and shareholders. In addition to his role as Chairman of the Board with Blade, Mark currently serves as Chief Executive Officer at Attralus and a board member at Sarissa Capital Acquisition Corp. (NASDAQ: SRSAU). He is also a strategic advisor to health care companies and investment groups.
Throughout a career defined by deep operational and commercial experience, Mark has led significant acquisitions and divestitures; reshaped country and global business operations; launched numerous breakthrough medicines; delivered growth strategies to achieve market leadership; and played key roles in pipeline governance. He has held senior roles in companies that include The Medicines Company, Merck & Co., Purdue Pharmaceuticals, Zeneca Group, ICI Pharmaceuticals and Roussel Labs, and has led markets that include the United States, Japan, South Korea, Australia and New Zealand.
Mark’s most recent executive role was CEO and Board member of The Medicines Company (NASDAQ: MDCO) which was subsequently sold to Novartis (NYSE: NVS) for $9.7B.
Gregory Bell, M.D. earned his medical degree from Cornell University Medical College and completed his training in Internal Medicine and Rheumatology at Brown University and the University of California, San Francisco (UCSF), respectively.
In 1996, he joined Merck & Co., Inc and contributed to several products that received regulatory approval including Vioxx®, Etoricoxib® and Cancidas®. Greg returned to California in 2000, joined Abgenix, Inc. and became Vice President of Clinical Development, Biometrics and Clinical Operations with responsibilities across the portfolio including Vectibix®. In 2005 Greg joined KAI Pharmaceuticals as Senior Vice President, Development and Chief Medical Officer. While at KAI he discovered peptide agonists of the calcium sensing receptor and led the global development of Parsabiv® until Amgen acquired KAI in 2012. In 2013 Dr. Bell joined Genentech as Vice President, Safety Risk Management of the Immunology, Infectious Disease and Ophthalmology portfolio. While at Genentech, Greg built and led a team that supported over a dozen different clinical programs and contributed to multiple NME and supplemental global filings across the portfolio.
Prior to joining Attralus, Greg was SVP of Development at Global Blood Therapeutics. Dr. Bell is an Assistant Clinical Professor of Medicine at UCSF and is a member of the American College of Rheumatology.
Glen Firestone has a distinguished 25-year career as an executive leader spanning biotech, pharmaceutical, and technology companies. He has utilized his deep commercial and strategic expertise to build businesses, launch breakthrough therapies, improve patients’ lives, and create value.
Prior to joining Attralus, Glen led a consulting business advising biotech companies on corporate strategy, commercialization, marketing, product development, market access, portfolio prioritization, business development, and valuations. Glen also served as a strategic advisor to Valo Health, a technology company using machine intelligence to accelerate the discovery and development of novel treatments. Prior to Valo, he was VP, Head of Commercialization at Tmunity Therapeutics, a private clinical-stage biotech company developing novel CAR-T cell therapies. In addition, Glen spent 20 years as a commercial executive at Merck with responsibility for leading many Global and U.S. franchises, including the cardiovascular business, delivered growth strategies building multibillion dollar product portfolios, successfully launching 12 innovative therapies, negotiating business development deals, and building partnerships.
Glen earned an M.B.A from Harvard Business School and a B.S in Mechanical Engineering from Rutgers University.
Benson Fong has over 30 years of experience in financial and business development activities in life science companies. He is a consulting CFO to startups and has served as Interim CFO at E-Scape Bio, ReCode Therapeutics, and GABAeron. Prior to this, he served as CEO of Lapis Pharmaceutical as well as Senior VP Corporate Development at CoTherix where he was responsible for in-licensing Ventavis® (iloprost) which was later FDA approved and successfully launched.
Benson’s prior experience also includes being the first VP for venture debt lending at Imperial Bank/Comerica, serving as CFO at Cibus Pharmaceutical, Controller at Matrix Pharmaceuticals, and Division Controller in Express Banking at Wells Fargo Bank. He was also a tax accountant and CPA at Arthur Young & Co. after he received his BS in Biology from the University of Oregon. His responsibilities have included filing S-1s, equity and debt financing and product licensing.
Dr. Gorti has a rich and diverse background including roles in corporate development and investor relations, as an investment analyst covering biotechnology companies, as a physician trained in otolaryngology & head and neck surgery, and as a clinical and translational researcher.
In his previous tenure with The Medicines Company, he served as Senior Vice President of Investor Relations and played an integral role in value-building initiatives, as well as working in earlier roles in business development and strategy.
Prior to roles with biopharmaceutical companies, Gorti was a biotechnology industry equity research analyst (sell side) with leading financial institutions, including JP Morgan, Piper Jaffray and Rodman & Renshaw.
Spencer brings deep strategic and operational expertise with 24 years in drug development and commercialization in both large and small biotech. He has dedicated more than 13 years of his career to amyloid-related diseases, including AL and ATTR amyloidosis, Alzheimer’s and Parkinson's disease, and has authored over 30 scientific publications in amyloidosis.
Prior to founding Attralus, he was VP, Head of Global Strategy at Akcea and Ionis, and responsible for the ATTR franchise strategy. Prior to that, he was VP, Head of Development Operations and Medical Affairs for Prothena Biosciences leading programs in AL and ATTR Amyloidosis. In addition, Spencer has significant leadership experience in clinical development, portfolio program management and commercial operations at Genentech, Elan, Janssen and Ultragenyx contributing to bring numerous therapeutic candidates from development to patients in need, including Avastin®, Rituxan®, Lucentis®, Tysabri®, Crysvita®, Mepsevii®, and Dojolvi®.
Spencer received a BS in Neuroscience from Vanderbilt University, and an MBA from the Paul Merage School of Business at the University of California.
Mike Klein joins Attralus with over 30 years of experience in the biotechnology industry. He has spent his career working in various aspects of CMC development of therapeutic proteins, including 25 years with monoclonal antibodies and related proteins (Fc fusions, bispecifics, multifunctionals).
Mike most recently served as Vice President of Analytical Development at Nektar Therapeutics, serving on the leadership team of the company’s Product Development and Manufacturing group. Mike has also served as a CMC scientific leader at Agenus, Atara Bio, Xencor, Protein Design Labs, and Amgen. At Atara, Mike led the CMC function at the company’s outset, moving their Fc fusion proteins and MAbs into clinical development as the company moved from pre-IPO to public.
Mike received his Ph.D. in Biological Chemistry from UCLA and was a postdoctoral fellow in the Division of Immunology at the Beckman Research Institute of the City of Hope.
Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis and has worked in the field of amyloidosis for over 25 years.
He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis.
Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics. We are developing pan-amyloid targeting agents that facilitate diagnosis, and the development of novel immunotherapies designed to clear amyloid fibrils in patients with systemic amyloid diseases. We aim to improve the diagnosis and treatment of systemic amyloid diseases, such as light chain (AL), transthyretin (ATTR), and LECT2 amyloidosis, to increase patient survival and quality of life.
Attralus’ technology has broad applications and the potential to address up to 30 systemic amyloid based diseases. Attralus has a diagnostic imaging agent currently in a ph 1/2 trial, positioned to potentially be the first approved diagnostic specifically for amyloidosis. The company also has 2 novel therapeutic fusion proteins, directed at amyloid removal, that are in pre-clinical development
Headquartered in South San Francisco and founded in 2019, Attralus has recently completed a Series A funding with VenBio to carry forward its mission to improve the lives of systemic amyloidosis patients
The AD/Director, Program Management will be responsible for providing both strategic and hands-on program and project management expertise. Initially reporting directly to the CEO, the AD/Director will be responsible for creating the program plan and budget and providing daily coordination and tracking of critical activities, assuring all milestones and deliverables are met. The Director will be responsible for developing the program management processes and procedures for the company, determining appropriate software and other tools, structuring regular meetings and communication within the company and with external collaborators.
• Collaborate with the management team to provide project management leadership and execution activities within the company and between external partners and Attralus teams.
• Develop and execute integrated cross-functional project plans with established goals, milestones, timelines and budget, with a key focus on bringing pre-clinical therapeutic programs into early clinical development
• Conduct and direct day-to-day program activities to meet milestones; monitoring critical path activities to ensure delivery of program objectives.
• Drive planning for key drug development milestones.
• Maintain effective communication with the management team through oral and written correspondence and ensure adequate documentation of each communication.
• Always use/model/maintain/promote best practices in Program Management, including the use of agendas, minutes, dashboards, maintain document repository, establish and implement templates, tools, and processes to drive efficiency, alignment, communication, and effective planning.
• Create and maintain easily accessible, high level program documents in electronic format.
• Recommend, manage and train on necessary software and tools.
• Identify, develop and/or maintain an appropriate electronic platform (SharePoint, Shared Folders, etc.) for reporting/archiving/documentation of relevant program information, records, etc.
• Conduct risk management, contingency and scenario planning using appropriate program management tools.
• Identify program issues or resource gaps and facilitate resolution.
• Communicate program information and support development of program presentations to senior leadership, board members, investors and other key stakeholders as appropriate.
• Contribute to budgetary planning at the program level.
• Facilitate adherence to Aurora’s governance processes; work with key stakeholders to prepare for those interactions; lead/support as appropriate. Ensure implementation of governance decisions.
• Minimum of a BA/BS in a scientific disciplined is required, Advance degree preferred
• 7+ years of program management or equivalent experience in a pharmaceutical or biotechnology organization.
• Experience with research/pre-clinical and early clinical development project planning required. PM Certification is a plus.
• Rare disease experience a strong plus (not required).
• Desire and ability to work in a start-up, fast paced organization where you will wear many hats.
• Must have excellent verbal and written communication skills as well as exceptional organizational capability.
• Ability to drive program plans and timelines (across multiple functional areas) is essential. Proven success in goal setting, prioritization and time management is required.
• Understanding of FDA and/or EMA quality and regulatory processes. Prior experience with regulatory filings is desirable.
• Experience working with external partners is desirable.
• Ability to work independently in decision-making and resolution of program obstacles and conflicts.
• Familiarity with developing budgets and forecasting is desirable.
• Ability to function autonomously, with an appreciation of detail while being cognizant of “the big picture.”
• Have a patient-first mindset. All decisions made with patients in mind.
• Proficiency with Microsoft Word, Excel, PowerPoint, and Project is required.
Benefits/Equal Opportunity Employer
Attralus, Inc. offers both comprehensive benefits and Paid Time Off (PTO) plans for employees, which begin on the first day of employment.
Attralus, Inc. is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.